News
Radioligand Therapy Improves PFS and Responses in SSTR+ Grade 2/3 GEP-NETs
The use of lutetium 177Lu dotatate (Lutathera) and high-dose long-acting octreotide as frontline treatment for patients with newly diagnosed somatostatin receptor (SSTR)-positive, grade 2 and 3, advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) led to significant improvements in progression-free survival (PFS) compared with high-dose long-acting octreotide alone.
"This would represent a new indication for first-line treatment of GEP-NETS. In addition, this would represent the first theranostic agent FDA approved for use in the 1st line setting," said Kunz, associate professor of Internal Medicine (Medical Oncology); director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center; chief, GI Medical Oncology; vice chief, Diversity, Equity, and Inclusion, Medical Oncology.
Source: Targeted Oncology